The estimated Net Worth of Gregory F Covino is at least 37.5 千$ dollars as of 20 December 2018. Mr. Covino owns over 3,055 units of Novavax stock worth over 37,546$ and over the last 13 years he sold NVAX stock worth over 0$. In addition, he makes 0$ as Chief Financial Officer、 Executive Vice President at Novavax.
Gregory has made over 14 trades of the Novavax stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 3,055 units of NVAX stock worth 37,546$ on 20 December 2018.
The largest trade he's ever made was exercising 3,055 units of Novavax stock on 20 December 2018 worth over 37,546$. On average, Gregory trades about 277 units every 79 days since 2012. As of 20 December 2018 he still owns at least 3,055 units of Novavax stock.
You can see the complete history of Mr. Covino stock trades at the bottom of the page.
Gregory F. Covino has been appointed as Chief Financial Officer, Executive Vice President of the Company effective 11/16/2020. Prior to joining the Company, Mr. Covino was Group CFO at GlaxoSmithKline’s TESARO Oncology Division, where he also served as Senior Vice President and Chief Accounting Officer since July 2018. He previously served as Chief Accounting Officer at Biogen Inc. since April 2012. He held earlier positions as Vice President, Corporate Internal Audit and Vice President, International Finance for Boston Scientific Corporation. Earlier in his career, Mr. Covino spent 10 years at international accounting and consulting firm PricewaterhouseCoopers.
Gregory Covino is 53, he's been the Chief Financial Officer、 Executive Vice President of Novavax since 2020. There are 19 older and 3 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.
Gregory's mailing address filed with the SEC is C/O NOVAVAX, INC., 21 FIRSTFIELD ROAD, GAITHERSBURG, MD, 20878.
Over the last 23 years, insiders at Novavax have traded over 136,088,511$ worth of Novavax stock and bought 2,908,869 units worth 5,634,467$ . The most active insiders traders include David M Mott、Rajiv I. Modi、Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of 907,678$. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth 8,050$.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: